🔥Telegram İfşa

🫀 In patients presenting with #STEMI, requiring rotational atherectomy (RA), RA seems to be feasible with a high procedural success rate and low in-hospital mortality. Findings from the ROTA-STEMI Network MedUni Wien 👉 onlinecjc.ca/article/S0828-… #CJC #OpenAccess

Coronary access simulation ♦️after #TAVI and #redoTAVI ♦️in Liverpool 🇬🇧 🎵 🔹at the ACE Valve Academy BostonSci Cardiology 🏅Top quality case examples by Arif Khokhar & Alessandro Beneduce. 👉Follow them at #PCRLV! 🔍Simulation is part of the SHD training #EAPCI Vilhelmas Bajoras 🇱🇹🇺🇦🌻 Norman Mangner

Terrific week in Germany at Klinicum Herz Frankfurt, Heidelberg, Düsseldorf, Karlsrhue, and DGK Hamburg. Amazing work in AMICS and HF-Shock with LV unloading. This field is truly inspiring with many great patient survivors! Gregg W. Stone MD C. Michael Gibson MD William W. O'Neill Navin Kapur

#AHA24: How does the benefit of microaxial flow pumps in cardiogenic shock vary by age? In a new analysis of the DanGer Shock trial, Dr. Jacob Møller & team at Research Unit of Cardiology, OUH find that these devices may not benefit older patients (>77 y/o) bit.ly/3Z56S3L #JACC #cvGeri

Very important secondary analysis from the DanGer Shock trial. Would need confirmation in a larger trial against the background of an aging population.

2025 US guidelines for the management of ACS (STEMI and NSTE-ACS) just released. Insertion of a microaxial flow pump (Impella) to prevent death in in cardiogenic shock has received a class IIa LOE B-R recommendation. IABP and VA-ECMO are class III for rourine use.

Hot in press. See our latest paper showing that a DanGer Shock like patient profile is associated with a lower 180-day mortality in STEMI-CS patients treated by a microaxial flow pump Chuck Simonton Gregg W. Stone MD Babar Basir Johnson & Johnson MedTech | HeartRecovery for HCPs onlinelibrary.wiley.com/doi/full/10.10…

Could a shock #Profile help predict who survives STEMI-CS? 🧠 DanGer Shock–like profile linked to lower 180-day #mortality in a real-world registry! 💡bit.ly/ESCHF_DanGer Piotr Ponikowski Norman Mangner Jan Biegus #Shock #heartfailure

My last day as CMO at Abiomed was quite memorable as Mike, Andrew, Devi (all prior or current Worldwide Presidents) and Jacob Møller (DanGer Shock) joined me in the studio for my CMO Corner show. What an honor it’s been… Michael Minogue Navin Kapur Gregg W. Stone MD B. Hadley Wilson MD

Out now: Kidney Injury in HF-related #CardiogenicShock is linked to higher 30-day mortality & complications. Great collaboration! Benedikt Schrage 🔗doi.org/10.1002/ejhf.3……Also great data: Rachna Kataria, MD #CSWG – WRF in 1/3 of CS pts = 2× ↑ mortality📷 bit.ly/4coLN9F

New EuroIntervention issue is out! This edition features: • The PROTECT IV trial – redefining MCS in high-risk PCI • Denmark’s shift in routine use of prasugrel/ticagrelor • OCT vs angiography in ACS patients • Blood pressure effects after renal denervation • Renal

PROTECT IV Trial A large-scale, multicentre RCT investigating whether routine use of Impella during high-risk PCI in patients with complex CAD and reduced LVEF confers clinical benefit compared with standard care. Norman Mangner Gregg W. Stone MD Amir Kaki, MD George Dangas, MD, MACC, MSCAI Dr. Jeffrey W. Moses